Global Postoperative Nausea and Vomiting Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Get Exclusive Sample PDF of this Report Here

Postoperative Nausea and Vomiting Treatment Market Analysis

The postoperative nausea and vomiting treatment market is advancing rapidly with the latest methods and technologies. Innovations such as antiemetic drugs, acupuncture, and enhanced recovery programs are transforming patient care. Growth is fueled by increasing surgical procedures worldwide, emphasizing the need for effective management strategies to improve patient outcomes and reduce healthcare costs.                      

Postoperative Nausea and Vomiting Treatment Market Size

The global postoperative nausea and vomiting treatment market size was valued at USD 2.19 billion in 2023, is projected to reach USD 3.37 billion by 2031, with a CAGR of 5.52% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Get Exclusive Sample PDF of this Report Here

Postoperative Nausea and Vomiting Treatment Market Analysis and Size

Postoperative nausea and vomiting (PONV) is commonly treated with antiemetic medications such as ondansetron and metoclopramide. These drugs target serotonin and dopamine receptors to prevent or alleviate symptoms. Non-pharmacological approaches such as acupuncture or ginger supplements may also be used adjunctively. Treatment choice depends on patient risk factors, surgery type, and individual response to medications.           

Postoperative Nausea and Vomiting Treatment Market Dynamics

Drivers

• Increasing Surgical Procedures

The increasing number of surgical procedures globally directly correlates with a higher incidence of postoperative nausea and vomiting (PONV), amplifying the demand for effective treatments. For instance, in 2023, over 300 million surgeries were performed worldwide, contributing to a significant rise in PONV cases. This trend underscores the critical need for advanced therapies and medications tailored to mitigate PONV risks, thereby driving growth in the PONV treatment market.

• Growing Geriatric Population

The growing geriatric population, with its increased susceptibility to postoperative nausea and vomiting (PONV) due to age-related physiological changes, is a significant driver for the market. As older adults undergo more surgeries for chronic conditions and age-related ailments, there is a rising demand for specialized PONV treatments. For instance, pharmaceutical companies are developing targeted antiemetic therapies tailored to address the unique needs and sensitivities of elderly patients, thereby driving market expansion. 

Opportunities

• Patient Preference for Non-Invasive Treatments

Patient preference for non-invasive treatments is a key opportunity  in the postoperative nausea and vomiting (PONV) treatment market. As patients increasingly seek effective yet minimally invasive solutions, innovations such as transdermal patches for antiemetic delivery are gaining traction. These methods offer convenience and comfort post-surgery, aligning with patient expectations for reduced side effects and quicker recovery. This trend fuels market growth by encouraging the development of more patient-centric PONV management options.

• Advancements in Anesthesia Techniques

Advancements in anesthesia techniques, such as the use of volatile anesthetics with lower emetogenic profiles and enhanced monitoring technologies, have significantly reduced the incidence of PONV in many patients. However, high-risk individuals, such as those with a history of motion sickness or specific genetic predispositions, still require targeted treatments. This dual impact drives innovation in PONV treatments, focusing on personalized therapies to address diverse patient needs and market demands.

Restraints/Challenges

• Limited Efficacy of Current Therapies

The limited efficacy of current antiemetic drugs in providing complete relief for all patients poses a significant hindrance to the postoperative nausea and vomiting (PONV) treatment market. This inadequacy underscores the pressing need for new therapeutic options with enhanced efficacy profiles. As patients experience varying degrees of nausea and vomiting post-surgery, the market's growth potential is restricted by the persistent challenge of ensuring universally effective treatment outcomes.

• Preference for Non-Pharmacological Interventions

The preference for non-pharmacological interventions, such as acupuncture, acupressure, or dietary modifications, poses logistical and acceptance challenges in integrating these options into clinical practice. This preference can hinder the growth of the PONV treatment market by diverting attention and resources away from pharmacological solutions that have traditionally dominated treatment strategies, complicating standardization and efficacy evaluation in medical settings.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Postoperative Nausea and Vomiting Treatment Market Scope

The market is segmented on the basis of treatment type, application, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Serotonin Receptor Antagonists
• Steroids
• Dopamine Antagonists
• Neurokinin NK-1 Receptor Antagonists
• Non-pharmacological Treatment

Application

• Postoperative Nausea and Vomiting (PONV)
• Chemotherapy-Induced Nausea and Vomiting (CINV)
• Motion Sickness
• Pregnancy
• Others

 End-Users

• Clinic
• Hospital
• Others

 Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Postoperative Nausea and Vomiting Treatment Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, treatment type, application, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the Postoperative nausea and vomiting treatment market, driven by major key players, technological advancements, a robust healthcare sector, rising disease prevalence, and heightened health awareness in the region.

Asia-Pacific is expected to grow the Postoperative nausea and vomiting treatment market during the forecast period, driven by increasing research and development activities, rising investment in the healthcare sector, and growing government support in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Postoperative Nausea and Vomiting Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Acacia Pharma Group Plc (U.K.)
• Sanofi (France)
• Novartis AG (Switzerland)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• ANI Pharmaceuticals, Inc. (U.S.)
• Camurus AB (Sweden)
• Helsinn Healthcare SA (Switzerland)
•  Eisai Co., Ltd. (Japan)
• Merck & Co., Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• GSK plc. (U.K.)

Latest Development in Postoperative Nausea and Vomiting Treatment Market

• In 2023, Acacia Pharma introduced Barhemsys and Amisulpride as primary antiemetics for managing PONV. Barhemsys, an intravenous selective dopamine D2 and D3 receptor antagonist, effectively prevents and treats PONV, gaining regulatory approval in the US and Europe for its high efficacy
• In 2023, Roche developed a patient-controlled analgesia (PCA) system for PONV. This system administers opioids and antiemetics via a pump, significantly reducing PONV incidence and enhancing patient satisfaction

SKU-64319